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Abstract 1 
Glutamate is the major excitatory neurotransmitter of the central nervous system, with 2 
the branched-chain amino acids (BCAAs) acting as key nitrogen donors for de novo 3 
glutamate synthesis.  Despite the importance of these major metabolites, their 4 
metabolic pathway in the human brain is still not well characterised.  The metabolic 5 
pathways that influence the metabolism of BCAAs have been well characterised in rat 6 
models.  However, the expression of key proteins such as the branched-chain α-7 
ketoacid dehydrogenase (BCKD) complex and glutamate dehydrogenase isozymes 8 
(GDH) in the human brain is still not well characterised.  We have used specific 9 
antibodies to these proteins to analyse their distribution within the human brain and 10 
report, for the first time, that the E1α subunit of the BCKD is located in both neurons 11 
and vascular endothelial cells.  We also demonstrate that GDH is localised to 12 
astrocytes, although vascular immunolabelling does occur.  The labelling of GDH was 13 
most intense in astrocytes adjacent to the hippocampus, in keeping with glutamatergic 14 
neurotransmission in this region.  GDH was also present in astrocyte processes 15 
abutting vascular endothelial cells.  Previously, we demonstrated that the branched-16 
chain aminotransferase (hBCAT) proteins were most abundant in vascular cells 17 
(hBCATm) and neurons (hBCATc).  Present findings are further evidence that BCAAs 18 
are metabolised within both the vasculature and neurons in the human brain.  We 19 
suggest that GDH, hBCAT and the BCKD proteins operate in conjunction with 20 
astrocytic glutamate transporters and glutamine synthetase to regulate the availability 21 
of glutamate.  This has important implications given that the dysregulation of glutamate 22 
metabolism, leading to glutamate excitotoxicity, is an important contributor to the 23 
pathogenesis of several neurodegenerative conditions such as Alzheimer’s disease.   24 
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Abbreviations 1 
AD, Alzheimer’s disease; BCAA, branched-chain amino acids; hBCAT, human 2 
branched-chain aminotransferase; BCKA, branched-chain a-keto acid; BCKD, 3 
branched-chain a-keto acid dehydrogenase complex; CA, cornu ammonis area; DAB, 4 
3.3’-diaminobenzidine; DAPI, 4',6-Diamidino-2-Phenylindole; DPX, distyrene 5 
plasticiser xylene; EDTA, ethylenediaminetetraacetic acid; GABA, gamma-amino 6 
butyric acid; GDH, glutamate dehydrogenase; GFAP, glial fibrillary acidic protein; 7 
hBCATc, human cytosolic branched-chain aminotransferase; hBCATm, human 8 
mitochondrial branched-chain aminotransferase; PBS, phosphate buffered saline; RT, 9 
room temperature; VWF, Von Willebrand factor.   10 
  11 
4 | P a g e  
Introduction 1 
The three-essential branched chain amino acids (leucine, isoleucine and valine) are 2 
key nitrogen contributors for the de novo synthesis of glutamate.  Studies on the rat 3 
retina demonstrated that inhibition of the cytosolic branched-chain aminotransferase 4 
(BCATc) decreased de novo glutamate synthesis by 30% (LaNoue et al., 2001; Lieth 5 
et al., 2001).  In humans, the first step in BCAA metabolism is catalysed by the 6 
branched-chain aminotransferases (hBCAT, EC 2.6.1.42), mitochondrial (hBCATm) 7 
and cytosolic (hBCATc).  These proteins mediate the transfer of the α-amino group 8 
from the BCAA to α-ketoglutarate to produce glutamate and the respective branched-9 
chain α-keto acid (BCKA – ketoisocaproate, ketomethylvalerate and ketoisovalerate; 10 
Scheme 1, reaction 1).  Studies in human tissue have demonstrated hBCATm 11 
expression within the vasculature, with hBCATc predominantly expressed in neurons 12 
(Hull et al., 2012).  The second step in BCAA metabolism is considered the rate-limiting 13 
step, as the BCKAs are irreversibly oxidised by the branched-chain α-keto acid 14 
dehydrogenase (BCKD, EC 1.2.4.4) complex.  This produces branched-chain acyl Co-15 
A derivatives (Scheme 1, reaction 2), generating the Kreb’s cycle substrate acetyl-16 
CoA, and the Kreb’s cycle intermediate succinyl-CoA (Harris et al., 1986; Hutson et 17 
al., 2005).   18 
The BCKD complex is primarily regulated by phosphorylation and dephosphorylation 19 
of the E1 subunit by the BCKD kinase and BCKD phosphatase proteins, with 20 
phosphorylation inactivating the complex (Damuni et al., 1984; Damuni et al., 1987; 21 
Popov et al., 1991; Popov et al., 1992; Shimomura et al., 1990; Shimomura et al., 22 
2001; Wynn et al., 2000).  The distribution of the BCKD complex has yet to be 23 
determined in the human brain.  However, work in rat has demonstrated BCKD-E1α 24 
within neurons, where it is thought to contribute to the BCAA-BCKA shuttle and energy 25 
production (Cole et al., 2012).  The activity of the BCKD complex is influenced by the 26 
activity of the two glutamate dehydrogenase isoforms (GDH1 and GDH2; EC 1.4.1.3), 27 
which catalyse the conversion of glutamate into α-ketoglutarate (Scheme 1, reaction 28 
3) (Islam et al., 2010).   29 
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 1 
GDH1 is expressed in the liver and was previously detected in astrocytes within the 2 
human brain.  Conversely, the GDH2 protein is absent from liver and expressed in the 3 
human testes, kidney and brain, where it was also observed in astrocytes in the human 4 
cortex (Nissen et al., 2016; Spanaki et al., 2010; Spanaki et al., 2014; Spanaki & 5 
Plaitakis, 2012).  Both GDH isoforms are considered mitochondrial, however GDH 6 
activity has also been associated with the nucleus (di Prisco et al., 1968; Lai et al., 7 
1986) and the endoplasmic reticulum (Colon et al., 1986; Lee et al., 1999) of rat tissue.  8 
The GDH proteins link glutamate metabolism with the Kreb’s cycle, and whilst the 9 
reaction is potentially reversible, it is accepted that in the brain this reaction is 10 
predominantly directed to metabolise glutamate (Lorin et al., 2013; Yudkoff et al., 11 
1994; Li et al., 2012).  GDH is regulated through many factors including the availability 12 
of purine nucleotides (ADP, ATP, GTP and NADH), steroid hormones and L-leucine.  13 
GTP is the predominant negative regulator of GDH1, activating the protein when cell 14 
energy production is reduced.  GDH2 lacks such a regulator and is constitutively active 15 
in a metabolically active cell (Spanaki et al., 2010).  The predominant positive 16 
regulators of both enzymes are ADP and L-leucine (increasing activity by up to 14-fold 17 
and 9.7-fold, respectively), resulting in acute sensitivity of these proteins to the activity 18 
of hBCAT and the BCKD complex (Erecinska & Nelson, 1990; Mastorodemos et al., 19 
2005; Plaitakis et al., 2013; Smith & Stanley, 2008; Tomita et al., 2011). 20 
Previous work by Islam et al. (2007, 2010) using pure protein and rat models, 21 
demonstrated that hBCATm is able to form a protein complex with the BCKD subunit 22 
E1α and GDH1.  This complex allows channelling of the BCKAs to the E1α subunit, 23 
increasing BCKA decarboxylation 12-fold.  The GDH1 protein then binds to the 24 
pyridoxamine-5’-phosphate form of BCATm and increases the recycling of the BCAT 25 
cofactor pyridoxal-5’-phosphate, also replenishing α-ketoglutarate (Islam et al., 2007; 26 
Scheme 1
hBCAT
BCAA + α-ketoglutarate                Glutamate + BCKA
BCKD
BCKA + NAD+ + CoA                 Branched chain-CoA + CO2 + NADH + H+
GDH
Glutamate + H2O + NAD+ α-ketoglutarate + NH3 + NADH + H+
Reaction 1
Reaction 2
Reaction 3
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Islam et al., 2010).  Despite the importance of BCAA and glutamate metabolism in the 1 
human brain, it has not been established whether a similar process occurs within this 2 
tissue.  Establishing a complete understanding of BCAA and glutamate metabolism is 3 
of particular relevance to diseases where these metabolites contribute to the 4 
pathological process, such as maple syrup urine disease and Alzheimer’s disease, 5 
respectively. 6 
Our aim in this study was to examine the distribution of the GDH protein and the BCKD 7 
complex in the human brain, to ascertain whether the previously described BCAA 8 
shuttle (Hull et al., 2012) could be extended to include these key metabolic proteins.  9 
This previous work provided the first evidence of transaminases (hBCATm) in the 10 
endothelial layer operating as a support network to astrocytes mediating the fine-11 
tuning of glutamate homeostasis.  We further proposed that under normal 12 
physiological conditions, the BCAAs are taken up by neuronal cells, where hBCATc 13 
controlled metabolism acts as a pathway to replenish the glutamate pool.   14 
For the first time, the BCKD complex E1α subunit and the GDH proteins were mapped 15 
to the human brain.  In agreement with findings of Cole et al., (2012) in the rat, we 16 
report that BCKD complex E1α is in neurons, widely distributed throughout the brain 17 
in a variety of neuronal types.  However, in addition to observations in the rat, our 18 
findings highlight the expression of the BCKD complex E1α in endothelial cells 19 
throughout the brain vasculature.  In line with previous work (Spanaki et al., 2014), 20 
immunolabelling for GDH was predominantly expressed in astrocytes; however, 21 
labelling was also evident within the vasculature with weak labelling of cerebellar 22 
Purkinje cells.  We discuss the impact of these findings with respect to the human 23 
BCAA-BCKA shuttle and the regulation of glutamate production in the human brain.  24 
7 | P a g e  
Materials and Methods 1 
Materials 2 
Antibodies.  Rabbit polyclonal antibodies to BCKD-E1α (ab126173) and GDH1/GDH2 3 
(ab154027), goat polyclonal secondary antibody to rabbit Alexafluor® 488 (ab150077) 4 
and mouse Alexafluor® 568 (ab175473), mouse monoclonal antibody to glial fibrillary 5 
acidic protein (GFAP), a marker of astrocytes (ab10062) and b3-tubulin, a neuronal 6 
marker (ab78078) were purchased from Abcam (Cambridge, UK).  Mouse monoclonal 7 
antibody to von Willebrand factor (vWF), a marker of vascular endothelial cells 8 
(M0616), was purchased from Dako (Cambridge, UK).   9 
Immunohistochemistry.  Haematoxylin was purchased from SurgiPath 10 
(Peterborough, UK).  4',6-Diamidino-2-Phenylindole (DAPI)-containing hard-set 11 
mounting medium, peroxidase substrate 3,3’-diaminobenzidine (DAB), goat serum (S-12 
1000), biotin-labelled secondary antibody raised to IgG, and avidin (Vectastain ABC 13 
kit) were purchased from Vector labs (Peterborough, UK).  All other materials were 14 
purchased from Fisher Scientific (Loughborough, UK). 15 
 16 
Tissue preparation 17 
The study was approved by North Somerset and South Bristol Research Ethics 18 
Committee.  All brain tissue used in this study was from brains donated to the South 19 
West Dementia Brain Bank, University of Bristol.  The right hemi-brain had been fixed 20 
in 10% buffered formalin for 3 weeks before tissue blocks were cut and embedded in 21 
paraffin wax for detailed neuropathological assessment.  For this study, we examined 22 
18 brains, from people who were older than 60 years of age, had no history of 23 
dementia, and minimal or no neuropathological abnormalities as determined by Braak 24 
stage (Table 1) and small vessel disease score (Supplementary Table 1).   25 
Serial sections 7 µm in thickness were taken from multiple regions of the brain, 26 
including the frontal, temporal, parietal and occipital lobes, basal ganglia, midbrain, 27 
cerebellum and pons, and collected on APES coated glass slides.  Sections were 28 
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incubated at 60ºC overnight to aid adhesion prior to immunolabelling as described 1 
below.   2 
 3 
Immunohistochemistry 4 
The sections were dewaxed in histoclear (2 x 5 min) and dehydrated in 100% ethanol 5 
(2 x 3 min).  Endogenous peroxidase was quenched in 0.09% hydrogen 6 
peroxide/methanol solution for 30 min at room temperature (RT).  The slides were pre-7 
treated with citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0).  The slides 8 
were then washed (2 x 3 min) in phosphate buffered saline (PBS – 0.154 M NaCl, 1.86 9 
mM NaH2PO4.2H2O, 7.48 mM Na2HPO4.12H2O, pH 7.1) and non-specific binding sites 10 
were blocked with 10% horse serum in PBS (20 min, RT).  Sections were incubated 11 
overnight (20 h, 4°C) with primary antibody (1:3000 for GDH1/GDH2 and BCKD-E1α) 12 
in PBS containing 3% Marvel (GDH) or 3% BSA (BCKD-E1α).  The sections were 13 
washed in PBS (2 x 3 min) then incubated with biotinylated antibody to IgG for 20 min 14 
(Vectastain ABC kit).  The slides were washed again in PBS (2 x 3 min) and incubated 15 
with the avidin-biotin complex in PBS for 20 min (Vectastain ABC kit).  Slides were 16 
developed with DAB/H2O2 in distilled water (DAB substrate kit) for 10 min prior to 17 
immersion in copper sulphate solution (16 mM CuSO4.5H2O, 0.123 M NaCl) for 4 min, 18 
and subsequently counterstained with Harris’s haematoxylin (25% Gill haematoxylin).  19 
The slides were dehydrated in 100% ethanol (2 x 5 min), cleared in 100% clearene (2 20 
x 3 min) and mounted in Clearium.  Sections were viewed and imaged on a Nikon 21 
Eclipse 80i.   22 
 23 
Immunofluorescence  24 
The sections were dewaxed in histoclear (2 x 5 min) and dehydrated in 100% ethanol 25 
(2 x 5 min), followed by deionised water (2 x 5 min).  Sections were pre-treated with 26 
EDTA (1 mM, pH 8.0) for 30 min at 95°C, and washed (2 x 5 min) in deionised water 27 
followed by PBS (2 x 5 min).  Non-specific binding sites were blocked with 10% goat 28 
blocking serum in PBS for 20 min at RT.  Slides were incubated overnight (20 h, 4°C) 29 
with primary antibodies (1:500 for b3-tubulin; 1:100 for BCKD-E1α; 1:500 for 30 
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GDH1/GDH2; 1:500 for GFAP; 1:25 for VWF) in PBS containing 1% goat serum.  The 1 
slides were subsequently washed in PBS (2 x 5 min) and incubated with secondary 2 
antibody (1:100 for Alexafluor® 488 and Alexafluor® 568) for 1 h, washed in deionised 3 
water (2 x 5 min) and further blocked with Sudan black (0.3% Sudan black in 70% 4 
ethanol) for 2 min.  Slides were rinsed 8 times with PBS and washed in PBS (2 x 5 5 
min), mounted with DAPI and allowed to set for 30 min.  Images were acquired using 6 
Andor IQ software and a Nikon Eclipse TE300.   7 
  8 
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Results 1 
Antibody specificity for BCKD-E1α and GDH was tested by western blot analysis on 2 
pure protein and human brain homogenates (Figure 1A-B).  No cross reactivity with 3 
unrelated proteins was detected at the antibody concentrations used in these 4 
experiments.  For commercial antibodies raised to BCKD-E1α and GDH, a negative 5 
antibody control was included with each experiment.  For further confirmation, antigen 6 
absorption was also performed (at 200X molar excess) during IHC (Figure 1C-F).  7 
Labelling was completely prevented by prior incubation of the antibody with antigen.  8 
The figures are representative of the labelling observed in all 18 brains (Table 1). 9 
 10 
Distribution of BCKD-E1α in the human brain 11 
Labelling of BCKD-E1α was predominantly in neuropil and neurons throughout the 12 
brain (Figure 2A).  However, endothelial cells were also labelled (Figure 2B).  Certain 13 
astrocytic populations (notably Bergmann astrocytes) showed labelling but this was 14 
not a consistent feature (4/8 brains examined).  BCKD-E1α was detected in all regions 15 
of the brain examined, in both neurons and endothelial cells.  Labelling of neurons was 16 
stronger than that of endothelial cells.   17 
Within the hippocampus, neuronal labelling was strongest within the cornu ammonis 18 
area 4 (CA4), and weaker in successive CA regions through to CA1 (Figure 3A-C).  In 19 
the cerebral cortex, larger pyramidal cells were strongly immunopositive (Figure 3D, 20 
large arrows).  Vasculature labelling was observed throughout the cerebral cortex 21 
(Figure 3E) with only weak astrocytic labelling (9/18 brains examined), in the vicinity 22 
of the hippocampus and within the white matter (images not shown).  The 23 
subependymal and the ependymal tissue were immunopositive (Figure 3F).   24 
The molecular layer of the cerebellar cortex was diffusely immunopositive, with 25 
stronger labelling of the cell bodies of many Purkinje cells (Figure 4A-C).  Weak 26 
labelling was observed within the granule cell layer (Figure 4C).  The white matter was 27 
unlabelled apart from some immunopositive capillaries (Figure 4D-F) and small glial 28 
cells (probably oligodendrocytes).  Strong, exclusively neuronal labelling was 29 
observed within the dentate and fastigial nuclei (Figure 5A-C).  In the deep grey matter, 30 
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the neuropil was weakly labelled within the putamen, globus pallidus and 1 
hypothalamus.  As previously noted with respect to hBCATc, neurons of the 2 
hypothalamus, raphe nuclei, nucleus basalis of Meynert, pontine nuclei and locus 3 
coeruleus were immunopositive for BCKD-E1α (Figure 5D-F). 4 
 5 
Distribution of GDH in the human brain 6 
GDH immunoreactivity was expressed in astrocytes throughout the human brain 7 
(Figure 6A), with labelling of the astrocytic foot processes adjacent to the vasculature, 8 
in addition to the vasculature itself (Figure 6B-C).  Whilst GDH and GFAP were co-9 
localised, some astrocytic processes labelled for GDH but not GFAP.  This might be 10 
expected, as GFAP is located primarily in the larger processes and not those 11 
enveloping synapses where you would find GDH (Kosaka & Hama, 1986).  Most 12 
labelling for GDH was stippled/granular within the cytoplasm of the cell, in keeping 13 
with the mitochondrial restriction demonstrated in previous work (Spanaki et al., 2014).  14 
Not all astrocytes labelled for GDH but labelling was detected in all sections and areas 15 
studied.   16 
Within the hippocampus, GDH labelling was entirely astrocytic (Figure 7A-C).  There 17 
was also labelling of astrocytes in the neocortex and white matter (Figure 7D-E), but 18 
labelling in the white matter was less dense than that in the cortex.  The subpial 19 
feltwork of astrocytic processes was strongly immunopositive for GDH (Figure 7F) in 20 
all brain regions, not just in the cerebrum.  Neurons were largely unlabelled (16/18 21 
brains examined), apart from occasional pyramidal neurons in the vicinity of blood 22 
vessels (Figure 8A).  The labelling of perivascular astrocytic processes was evident 23 
throughout the cerebral cortex and cerebellum (Figure 8B); in places, the labelling also 24 
involved the adjacent endothelium (Figure 8C).   25 
Within the cerebellum (Figure 9A), there was punctate labelling in the processes of 26 
cells within the Purkinje cell layer, most likely to be Bergmann astrocytes (Figure 9B-27 
C).  The Purkinje cells themselves were unlabelled (12/18 brains examined) or weakly 28 
immunopositive (Figure 9B-C, small arrows).  Within the granule cell layer, rosette like 29 
structures (glomeruli) were immunopositive.  Within the deep cerebellar nuclei, there 30 
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was strong granular immunopositivity in small glial cells in contrast to the largely 1 
immunonegative neurons (Figure 9D-E).   2 
In addition to the granular/stippled cytoplasmic labelling of astrocytes in the cerebral 3 
cortex and deep grey matter structures, there was GDH immunopositivity of some glial 4 
nuclei within these regions (most notably in the putamen) (Figure 9F, arrows).  Whilst 5 
none of the brains was from a donor with dementia, in one brain GDH labelling 6 
occurred in conjunction with what appeared to be an amyloid plaque. 7 
 8 
Summary of distribution of BCKD-E1α and GDH in the human brain 9 
In summary, labelling of BCKD-E1α was associated with the neuronal cells and the 10 
vasculature in all brain regions studied, reminiscent of the distribution of hBCATc and 11 
hBCATm proteins (Hull et al., 2012).  However, the labelling of blood vessels was 12 
weaker and less consistent than that of neurons.  GDH was detected in all brain 13 
regions studied and was mainly within astrocytes.  There was strong labelling of GDH 14 
in regions containing glutamatergic neurons – likely associated with 15 
neurotransmission within this region.  Furthermore, close association of GDH positive 16 
astrocytic processes with the vasculature and in the deep nuclei of the cerebellum 17 
suggest additional roles for this protein.   18 
  19 
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Discussion  1 
The BCKD complex and the GDH isoenzymes play a key role in brain glutamate 2 
metabolism.  However, to date most of the information we have of their distribution 3 
within the brain is limited to data from small animal studies.  Previous work from this 4 
group has already demonstrated key differences between the expression of BCATm 5 
within the human brain and that in lower mammals such as rats (Cole et al., 2012; Hull 6 
et al., 2012).  Current findings indicate that within the human brain, BCKD-E1α is 7 
neuronal, supporting its proposed role in neuronal BCAA metabolism.  GDH was 8 
primarily localised to astrocyte populations of the human brain, as in rodents 9 
(Subbalakshmi & Murthy, 1985; Zaganas et al., 2001; Zaganas et al., 2012).  However, 10 
we have shown that, BCKD-E1α and GDH can also be detected within the vasculature 11 
of the human brain.  These findings add complexity to our interpretation of the roles of 12 
these proteins in BCAA and glutamate metabolism. 13 
Our understanding of the contribution of BCAAs to glutamate production is based on 14 
ex vivo and in vivo animal model [15N] studies, in which BCAAs (particularly leucine) 15 
contributed approximately 25% of the nitrogen for glutamate synthesis (Yudkoff et al., 16 
1983; Kanamori et al., 1998).  We have previously demonstrated that hBCAT was 17 
strongly expressed within the human brain (Hull et al., 2012).  The hBCATc enzyme 18 
was localised to neurons, whereas hBCATm expression was associated with the 19 
vasculature.  We proposed that, in the human brain, hBCATc metabolises BCAAs for 20 
the transamination of α-ketoglutarate to glutamate, with hBCATm re-transaminating 21 
glutamate to cycle back into BCAAs.  The hBCATc-mediated transfer of NH3 for 22 
production of glutamate would require further metabolism of the BCKAs to prevent 23 
their re-transamination.  In muscle, it is thought that the expression of minimally active 24 
BCKD results in up to 80% re-transamination of BCKAs, the remainder of which are 25 
predominantly exported rather than completely metabolised to Krebs cycle 26 
intermediates (Matthews et al., 1981; Nissen & Haymond, 1981; Suryawan et al., 27 
1998).   28 
As in the rat study of Cole et al., (2012), the majority of BCKD-E1α labelled neurons 29 
were either glutamatergic (e.g. hippocampal granule cells), GABAergic (e.g. Purkinje 30 
cells) or cholinergic (e.g. motor neurons).  Reamination of BCKAs is well defined in 31 
many organs (Harper et al., 1984; Staten et al., 1984); however, our work also raises 32 
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the potential for complete BCAA metabolism within neurons expressing BCKD.  This 1 
is supported by previous documentation of very low levels (<1 mM) of BCKAs within 2 
the human brain (Keen et al., 1993; Matsuo et al., 1993), reflecting the formation of 3 
glutamate from BCAAs and the complete oxidation of BCKAs to the Kreb’s cycle 4 
substrate acetyl-CoA, and the Kreb’s cycle intermediate succinyl-CoA.  The labelling 5 
of BCKD-E1α varied in different parts of the cerebrum but was particularly strong within 6 
the hippocampus.  The strong labelling of BCKD-E1α in the CA4 region and weaker 7 
labelling towards the CA1 region mirrors the distribution of hBCATc (Hull et al., 2012).  8 
BCKD-E1α was primarily restricted to the somatic region of nerve cells, suggesting 9 
that the cell body is the primary site of BCKA oxidation.  In the human brain, BCKD-10 
E1α expression was also noted within the vasculature, unlike in the rodent model.  The 11 
metabolism of BCAAs within the vasculature may be similar to that in muscle, i.e. 12 
incomplete metabolism to BCKAs, which either re-transaminate glutamate or are 13 
released for further metabolism by other cells (e.g. neurons).  However, the expression 14 
of hBCATm, BCKD and GDH within vascular cells raises the possibility that complete 15 
metabolism of BCAAs occur, which could generate ATP for the active transport 16 
required in this cell type.  This would be in keeping with the reported active metabolon 17 
described by Islam et al., (2007 & 2010), in which hBCATm, the BCKD complex and 18 
GDH1 work to metabolise BCAAs completely and restore the Kreb’s cycle substrate 19 
acetyl-CoA, and the Kreb’s cycle intermediate succinyl-CoA.   20 
The absence of BCKD and hBCAT labelling within astrocytes indicates that BCAA 21 
oxidation is neuronal rather than astrocytic, and that this oxidation is largely complete.  22 
These findings do not rule out the possibility of translocation of BCKAs to neurons but 23 
make it unlikely that those BCKAs are produced by astrocytes.  Skeletal muscle is 24 
thought to be the predominant source of BCKAs metabolised in the liver, due to the 25 
relatively reduced expression of hBCAT within this organ (Suryawan et al., 1998).  26 
Suryawan et al., (1998) also noted that the BCKD in the human brain is predominantly 27 
active, with 59% of the expressed protein maintained in the active state.  Translocation 28 
of BCKAs from the bloodstream would depend on their transport across the blood-29 
brain-barrier (BBB).  The transport of ketoacids (e.g. α-ketoglutarate) across the BBB 30 
occurs via the organic anion transporter family – and it is possible the BCKAs are 31 
transported in this manner (Riedmaier et al., 2012).   32 
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Work by our group showed hBCATc expressed in magnocellular neurosecretory cells, 1 
the substantia nigra, the nucleus basalis of Meynert and the raphe nuclei (Hull et al., 2 
2012).  The expression of BCKD closely mirrors that of hBCATc within these cell types, 3 
supporting a role for hBCATc in cells that secrete a range of neurotransmitters and 4 
peptides.  The action of leucine as a potent secretagogue has already been reported 5 
for the hormone insulin, where ketoisocaproate but not leucine, required 6 
transamination to stimulate insulin secretion (Xu et al., 2001; Zhou et al., 2010).  7 
Regulation of leucine levels is likely to be important in regulating neurosecretory 8 
function, and the contribution of BCAA metabolism to this regulation warrants further 9 
investigation. 10 
Biochemical studies on mouse, rat and human tissue have detected GDH 11 
activity/immunoreactivity in both neurons and glia (Hohnholt et al., 2017; 12 
Subbalakshmi & Murthy, 1985; Zaganas et al., 2001; Zaganas et al., 2012).  Rothe et 13 
al., (1994) estimated that GDH activity in neurons is approximately 15% of that in 14 
astrocytes and was crucial for neurons to metabolise glutamine-derived carbon during 15 
glucose deprivation (Hohnholt et al., 2017).  Our work confirms the expression of GDH 16 
within many astrocytes, accounting for the predominance of glial activity; the detection 17 
within neurons was more selective and the immunolabelling weaker.  However, 18 
Burbaeva et al., (2002) purified three isoforms of GDH protein from human brain 19 
tissue, and it is possible that additional GDH reactions are occurring within the brain 20 
in glia or neurons through the activity of a different GDH isoform.   21 
Scant consideration has been given within the literature to GDH activity within the 22 
vasculature.  The study of Helms et al., (2012) was one of the first to consider the 23 
potential for glutamate metabolism within endothelial cells, corroborated by our study.  24 
The expression of both hBCATm and GDH suggests that the vasculature has the 25 
potential to metabolise BCAAs fully for energy, or to metabolise glutamate for recycling 26 
of α-ketoglutarate and BCAAs.  In health, the brain is protected from variations in 27 
plasma glutamate by restriction of entry of glutamate across the BBB.  However, 28 
glutamate efflux does occur and is affected by blood glutamate level (Hosoya et al., 29 
1999; Gottlieb et al., 2003; Zlotnik et al., 2008; Teichberg et al., 2009; Uchida et al., 30 
2011; Campos et al., 2012; Zlotnik et al., 2012).  The ability of the vasculature to 31 
metabolise glutamate may occur as a supplementary mechanism to the glutamate-32 
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glutamine cycle, whereby the hBCATm-BCKD-GDH metabolon works to metabolise 1 
BCAAs fully except in circumstances of excess glutamate (i.e. glutamate toxicity).  2 
Increased expression of hBCAT was previously observed in Alzheimer’s disease, 3 
perhaps as a response to an increase in glutamate (Ashby et al., 2015; Hull et al., 4 
2015a).  Conversely, if the metabolon exists only on the abluminal surface, it would 5 
function solely for the disposal of glutamate.   6 
The direction of GDH metabolism will be determined by substrate concentration and 7 
the expression of other key metabolic proteins.  The predominant action of GDH within 8 
the human brain is for the production of α-ketoglutarate from glutamate, allowing 9 
glutamate to contribute carbon to the Kreb’s cycle within the brain (McKenna et al., 10 
2016; Nissen et al., 2015).  This is likely to be of particular importance within astrocytic 11 
processes surrounding the vasculature, where ATP generation through glutamate 12 
metabolism may provide the energy required for active transport across the BBB 13 
(Figure 10).  Additionally, ammonia (NH3 - lipid soluble) produced in this reaction may 14 
then leave the brain; this process, together with glutamine export, constitutes a major 15 
mechanism by which the brain disposes of excess ammonia (Hawkins et al., 2002).  16 
In astrocytes, the ammonia may also be incorporated into the structure of glutamate 17 
to form glutamine, through the work of the glutamine synthetase enzyme.  This 18 
incorporation into glutamine is unlikely to be a major process at the astrocyte-19 
vasculature boundary but is part of the glutamate-glutamine cycle in the astrocyte cell 20 
body (Figure 10). 21 
The subcellular location of GDH is predominantly mitochondrial; however, we also 22 
found GDH immunopositivity within the nucleus of some cells.  Lai et al., (1986) 23 
previously observed GDH activity in both the mitochondrial and nuclear fractions of rat 24 
brain homogenate and our observations indicate that GDH is present within a subset 25 
of nuclei in the human brain as well.  Nuclear GDH was observed in a small proportion 26 
of glial cells, mainly within the putamen.  This nuclear presence raises interesting 27 
questions about additional functions of GDH, of which two have been proposed.  Rajas 28 
et al., (1996) noted that membrane-bound GDH in pig liver had microtubule-binding 29 
activity and suggested that GDH was involved in microtubule-dependent lysosome 30 
formation.  Purohit et al., (2013) reported that GDH acts as a histone H3-specific 31 
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protease in chicken liver, a process that relates directly to the regulation of gene 1 
expression. 2 
Another proposed function of GDH is in the regulation of autophagy, for which the 3 
relationship between GDH and leucine is important.  In a HeLa knockdown of GDH1, 4 
leucine failed to inhibit autophagy whilst inhibiting mTORC1 activity (Lorin et al., 2013).  5 
The authors proposed that GDH1 regulates autophagy (at least in part) through the 6 
modulation of mTOR but may also contribute to the production of ROS scavengers 7 
and Krebs cycle intermediates (further inhibiting autophagy).  We previously found 8 
hBCAT to be absent from astrocytes in the human brain, in contrast to findings in the 9 
rat (Hull et al., 2012; Hull et al., 2015b).  It is of note that astrocytes in the human brain 10 
lack the capacity to metabolise BCAAs, including leucine, a key activator of GDH.  The 11 
expression of glutamine-leucine counter-transporters on the surface of astrocytes 12 
(Bak et al., 2006), raises the possibility that astrocytes can serve as a partial leucine 13 
sink.  This would maintain high intracellular astrocyte levels of leucine to (1) supply 14 
neurons with leucine for glutamate production and (2) support astrocytic GDH activity 15 
for the continuous metabolism of glutamate for the production of free ammonia (to 16 
either be used in the production of glutamine or exported out of the brain) and α-17 
ketoglutarate (to be used for the production of ATP).   18 
 19 
In summary, this work builds upon previous work from this group (Hull et al., 2012) 20 
and provides further insight to the metabolism of BCAAs within the human brain and 21 
their association with the glutamate-glutamine cycle.  We propose that under normal 22 
physiological conditions, neurons are the main site of BCAA metabolism, where 23 
glutamate is replenished through hBCATc transamination and BCKD activity controls 24 
re-transamination of the BCKAs.  Metabolism of the BCAAs may also occur within the 25 
vasculature, likely contributing to the buffering of glutamate levels within the brain.  We 26 
propose that the vasculature may also be a site at which the hBCATm-BCKD-GDH 27 
metabolon described by Islam et al., (2007 & 2010) exists in vivo.  Without the 28 
expression of hBCAT or the BCKD complex in astrocytes (Hull et al., 2012), it is 29 
unlikely that BCAAs are metabolised within this cell type.  Our findings have 30 
implications for the understanding of neurotransmitter metabolism within the human 31 
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brain, and consequently of neurological diseases in which there is dysregulation of 1 
glutamate or BCAA homeostasis.   2 
  3 
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Figures 1 
 2 
Figure 1.  Specificity of the GDH and BCKD-E1α antibodies.  Western blot analysis 3 
of pure protein (50 ng) and human brain homogenate (10 µg).  A: Western blot analysis 4 
using anti-GDH.  B: Western blot analysis using anti-BCKD (E1a subunit).  C: 5 
Immunohistochemistry BCKD staining of the cerebellum.  D: Antigen incubation of 6 
serial section of panel C, at 200X molar excess showing complete removal of 7 
28 | P a g e  
immunoreactivity.  E: Immunohistochemistry GDH staining of the cerebellum.  F: 1 
Antigen incubation of serial section of panel E, at 200X molar excess showing 2 
complete removal of immunoreactivity. Scale: C, D, E and F, 25 µm, 40x magnification.  3 
 4 
 5 
Figure 2.  Co-localisation of BCKD-E1α to cell type within the cerebellum.  A: (From 6 
left to right).  Green immunofluorescence labelling BCKD-E1α, red immunofluorescence 7 
labelling β3 tubulin (a marker of neuronal cells) and finally a merge showing BCKD-E1α 8 
is present in neurons.  B: (From left to right).  Green immunofluorescence labelling 9 
BCKD-E1α, red immunofluorescence labelling VWF (a marker of vessels) and finally a 10 
merge showing BCKD-E1α is present in vessels.  Scale bar: A and B, 25 μm, 40x 11 
magnification. 12 
 13 
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 1 
Figure 3.  Staining of BCKD-E1α in the frontal and temporal lobe.  A: The 2 
hippocampal formation showing immunopositive neurons within the cornu ammonis 3 
area 4 (CA4) and CA3 regions.  B: Hippocampal region CA4 showing positive neuronal 4 
cells (small arrows) and a positive vessel (large arrow).  C: Hippocampal region CA2 5 
showing positive neuronal cells.  D: Small immunoreactive neurons (small arrows) and 6 
large pyramidal neurons (large arrows) within the temporal cortex.  E: Small 7 
immunoreactive neurons and a small vessel within the temporal cortex.  F: Ependymal 8 
tissue showing immunopositive cells within the frontal cortex.  Scale bar: A, 200 μm, 9 
4x magnification; B, C, E and F, 25 μm, 40x magnification; D, 100 µm, 10x 10 
magnification. 11 
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Figure 4.  Staining of BCKD-E1α in the cerebellum.  A: The cerebellum structure 3 
showing immunopositive neurons within the molecular layer.  B-C: Immunopositive 4 
Purkinje neurons within the molecular layer of the cerebellum with weak labelling of 5 
the granule cell layer.  D-F: The white matter of the cerebellum showing 6 
immunoreactive capillaries.  Scale bar: A, 200 μm, 4x magnification; B, C, E and F, 25 7 
μm, 40x magnification; D, 100 µm, 10x magnification. 8 
 9 
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 1 
Figure 5.  Staining of BCKD-E1α in the cerebellum and brainstem.  A: The dentate 2 
nucleus within the cerebellum.  B-C: Increased magnification of the dentate nucleus 3 
showing staining of small neurons.  D: The Raphe nuclei (large arrows) showing 4 
immunopositive neurons adjacent to the 4th ventricle (*) and medial longitudinal 5 
fasciculus (MLF).  E: Immunopositive neurons within the nucleus basalis of Meynert.  6 
F: The locus coeruleus showing immunopositive neurons.  Scale bar: A and D, 200 7 
μM, 4x magnification; B, C, E and F, 25 µm, 40x magnification.  8 
 9 
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Figure 6.  Co-localisation of GDH to cell type within the cerebellum.  A: (From left 2 
to right).  Green immunofluorescence labelling GDH, red immunofluorescence labelling 3 
GFAP (a marker of astrocytes) and finally a merge showing GDH is detected in 4 
astrocytes (small arrows).  B: (From left to right).  Green immunofluorescence labelling 5 
GDH, red immunofluorescence labelling GFAP (a marker of astrocytes) and finally a 6 
merge showing GDH is present in astrocytes surrounding vessels (small arrows).  C: 7 
(From left to right).  Green immunofluorescence labelling GDH, red 8 
immunofluorescence labelling VWF (a marker of vessels) and finally a merge showing 9 
GDH is present within certain vessels.  Scale bar: A, B and C, 25 μm, 4x magnification. 10 
 11 
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Figure 7.  Staining of GDH in the frontal and temporal lobe.  A: The hippocampal 2 
formation showing supportive immunopositive astrocytes within the molecular layer.  3 
B: Increased magnification of the granule cell layer of the dentate gyrus (DG) showing 4 
small immunopositive astrocytes.  C: Increased magnification of astrocyte staining 5 
showing both cell body and process labelling.  D: Immunoreactive astrocytes within 6 
the temporal white matter.  E: Increased magnification of immunoreactive astrocytes.  7 
F: Ependymal and subependymal tissue showing immunopositive cells within the 8 
frontal cortex.  Scale bar: A, 200 μm, 4x magnification; B, C, E and F, 25 μm, 40x 9 
magnification; D, 50 µm, 40x magnification. 10 
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Figure 8.  Staining of GDH in the temporal lobe and cerebellum.  A: Temporal 3 
cortex with labelling of large pyramidal neurons (small arrows) adjacent to an 4 
immunopositive vessel (*).  B: Cerebellar white matter showing perivascular astrocytic 5 
labelling.  C: Cerebellar white matter showing vessel staining.  Scale bar: A, 100 μm, 6 
10x magnification; B and C, 25 μm, 40x magnification. 7 
 8 
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Figure 9.  Staining of GDH in the cerebellum and putamen.  A: The cerebellum 2 
formation showing immunopositive cells within the molecular and nuclear layers.  B-3 
C: Granule cell layer with immunopositive purkinje cell (small arrow) and labelling 4 
within the nuclear layer (large arrow) likely representing a vessel or astrocytic 5 
processes.  Also present are immunopositive Bergman astrocytes at the level of the 6 
golgi cell layer (arrow head).  D: Dentate nuclei immunopositive for GDH.  E: Increased 7 
magnification of the dentate nuclei demonstrating negative neuronal staining with 8 
immunopositive astrocytes and astrocytic processes.  F: Nuclear presence of GDH 9 
(small arrow) within the putamen.  Scale bar: A and D, 200 μm, 4x magnification; B, 10 
C, E and F, 25 μm, 40x magnification. 11 
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Figure 10.  The glutamate-glutamine cycle and the supporting role of the hBCAT, 3 
BCKD and GDH proteins.  Glutamate is released from neuronal cells during 4 
excitatory neurotransmission.  Post-excitation, glutamate is taken up via excitatory 5 
amino acid transporters on astrocytes.  In astrocytes much of the glutamate undergoes 6 
amidation to glutamine by glutamine synthetase.  Glutamine is then released for 7 
uptake by neuronal cells, to replenish the glutamate pool through the action of 8 
glutaminase.  However, much glutamate can be lost through oxidation via glutamate 9 
dehydrogenase, or generation of glutathione/purines in astrocytes.  The glutamate-10 
glutamine cycle must work with other anapleurotic pathways to regenerate the 11 
neuronal pool of glutamate.  BCAA metabolism is thought to participate in nitrogen 12 
shuttling in the de novo synthesis of glutamate.  The BCAAs, particularly leucine, can 13 
pass easily through the blood brain barrier through an L system transporter.  Uptake 14 
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by neuronal cells results in transamination by hBCATc with α-ketoglutarate forming 1 
glutamate, contributing to the neuronal pool.  The BCKAs are completely metabolised 2 
via BCKD to produce Kreb’s cycle intermediates and avoid re-transamination of 3 
glutamate.  In addition to astrocytes, the endothelial cells of the vasculature play a key 4 
role in removing excess glutamate and regenerating neuronal pools of glutamate.  As 5 
levels of hBCATm are strongly expressed and GDH is also present in many vessels, 6 
we propose that glutamate is either transaminated to the BCAAs or metabolised by 7 
GDH.  The BCAAs can then re-enter the pool for glutamate generation, and the 8 
ammonia (NH3) generated by GDH activity can be exported from the brain.  9 
Abbreviations: BCAA, branched chain amino acid; BCKD, branched chain keto acid 10 
dehydrogenase complex; GDH, glutamate dehydrogenase; Gln, glutamine; Glu, 11 
glutamate; hBCAT, human branched chain aminotransferase.   12 
 13 
Table 1.  Clinical outcome for patients used in this study. 14 
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 Age Gender PM (delay) 
Brain 
weight (g) Hypertension 
Braak 
staging 
Cause 
of death 
Patient 1 62 M 4 1230 Yes 0 Ventricular failure 
Patient 2 80 F 39 750 No 0 Colon cancer 
Patient 3 71 M 25 1245 No 1 Ventricular failure 
Patient 4 82 F 35 1150 No 3 Myocardial infarction 
Patient 5 64 M 16 1475 No 0 Abdominal aortic aneurysm 
Patient 6 78 M 12 1200 No 2 Myocardial infarction 
Patient 7 80 M 67 1460 Yes 3 Pneumonia 
Patient 8 70 M 50 1380 No 2 Carcinomatosis 
Patient 9 72 F 24 1200 No 0 Unknown 
Patient 10 76 M 23 1450 No 2 Pneumonia 
Patient 11 73 M 35 1350 Yes 3 Heart failure 
Patient 12 80 M 48 1279 Yes (T) 0 Pneumonia 
Patient 13 94 F 21 1015 Yes 2 Adenocarcinoma 
Patient 14 87 M 24 1364 Yes 2 Acute renal failure 
Patient 15 94 M 40 1260 Yes 2 Debility of old age 
Patient 16 85 M 31 1337 Yes (T) 2 Ischaemic heart disease 
Patient 17 77 M 42 1351 Yes (T) 1 Pneumonia 
Patient 18 87 F 47 1262 No 3 Septicaemia, pneumonia 
F, Female; M, Male; PM, Post-mortem; (T) Requiring treatment.  Cause of death was determined at autopsy. 
 
 1 
 2 
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Supplementary figure 1.  Specificity of the GDH and BCKD-E1α antibodies.  2 
Immunohistochemical analysis of human brain sections, including antigen incubations.  3 
A: Immunohistochemistry BCKD staining of the cerebellum.  B: Antigen incubation of 4 
serial section of panel A, at 200X molar excess showing complete removal of 5 
immunoreactivity.  C: Immunohistochemistry GDH staining of the cerebellum.  D: 6 
Antigen incubation of serial section of panel C, at 200X molar excess showing 7 
complete removal of immunoreactivity. Scale: C, D, E and F, 50 µm, 10x magnification.  8 
 9 
Supplementary table 1.  Clinical outcome for patients used in this study. 10 
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 Age Gender PM (delay) 
Brain 
weight (g) Hypertension 
Treated 
hypertension 
SVD 
Frontal 
SVD 
Temporal 
Braak 
staging 
Cause 
of death 
Patient 1 62 M 4 1230 Yes No - - 0 Ventricular failure 
Patient 2 80 F 39 750 No No - - 0 Colon cancer 
Patient 3 71 M 25 1245 No No - - 1 Ventricular failure 
Patient 4 82 F 35 1150 No No - 0 3 Myocardial infarction 
Patient 5 64 M 16 1475 No No - - 0 Abdominal aortic aneurysm 
Patient 6 78 M 12 1200 No No - - 2 Myocardial infarction 
Patient 7 80 M 67 1460 Yes No 2 2 3 Pneumonia 
Patient 8 70 M 50 1380 No No - 0 2 Carcinomatosis 
Patient 9 72 F 24 1200 No No 2 2 0 Unknown 
Patient 10 76 M 23 1450 No No 1 1 2 Pneumonia 
Patient 11 73 M 35 1350 Yes No 0 0 3 Heart failure 
Patient 12 80 M 48 1279 Yes Yes 2 1 0 Pneumonia 
Patient 13 94 F 21 1015 Yes No 2 2-3 2 Adenocarcinoma 
Patient 14 87 M 24 1364 Yes No 2 1 2 Acute renal failure 
Patient 15 94 M 40 1260 Yes No 1 2 2 Debility of old age 
Patient 16 85 M 31 1337 Yes Yes 2 1 2 Ischaemic heart disease 
Patient 17 77 M 42 1351 Yes Yes 1 2 1 Pneumonia 
Patient 18 87 F 47 1262 No No 2 2 3 Septicaemia, pneumonia 
F, Female; M, Male; PM, Post-mortem; SVD, Small vessel disease.  Cause of death was determined at autopsy. 
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